Effects of once-daily teneligliptin on 24-h blood glucose control and safety in Japanese patients with type 2 diabetes mellitus: A 4-week, randomized, double-blind, placebo-controlled trial

Diabetes, Obesity and Metabolism

Volumn 14, Issue 11, 2012, Pages 1040-1046

  Eto, T ^a   Inoue, S ^b   Kadowaki, T ^c  

^a Internal Medicine Medical Co LTA PS Clinic   (Japan)

^b Medical Corporation Heishinkai OCROM Clinic   (Japan)

^c UNIVERSITY OF TOKYO   (Japan)

Author keywords

DPP 4 inhibitor; HbA1c; Teneligliptin; Type 2 diabetes mellitus

Indexed keywords

ALANINE AMINOTRANSFERASE; C PEPTIDE; CREATININE; GAMMA GLUTAMYLTRANSFERASE; GLUCAGON; GLUCAGON LIKE PEPTIDE 1; GLUCOSE; HEMOGLOBIN A1C; INSULIN; PLACEBO; TENELIGLIPTIN;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; BLOOD GLUCOSE MONITORING; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DIABETIC DIET; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG HALF LIFE; DRUG SAFETY; ELECTROCARDIOGRAM; EXERCISE; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; HYPOGLYCEMIA; INSULIN BLOOD LEVEL; JAPANESE; MAJOR CLINICAL STUDY; MALE; MAXIMUM PLASMA CONCENTRATION; MEAL; MULTICENTER STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; TIME TO MAXIMUM PLASMA CONCENTRATION; VITAL SIGN;

EID: 84867141883     PISSN: 14628902     EISSN: 14631326     Source Type: Journal    
DOI: 10.1111/j.1463-1326.2012.01662.x     Document Type: Article

References (10)

1. Kreymann B, Williams G, Ghatei MA, Bloom SR. Glucagon-like peptide-1 7-36: a physiological incretin in man. Lancet 1987; 2: 1300-1304.
2. Edwards CM, Todd JF, Mahmoudi M et al. Glucagon-like peptide 1 has a physiological role in the control of postprandial glucose in humans: studies with the antagonist exendin 9-39. Diabetes 1999; 48: 86-93.
3. Buteau J, Foisy S, Rhodes CJ, Carpenter L, Biden TJ, Prentki M. Protein kinase Czeta activation mediates glucagon-like peptide-1-induced pancreatic beta-cell proliferation. Diabetes 2001; 50: 2237-2243.
4. Xu G, Stoffers DA, Habener JF, Bonner-Weir S. Exendin-4 stimulates both beta-cell replication and neogenesis, resulting in increased beta-cell mass and improved glucose tolerance in diabetic rats. Diabetes 1999; 48: 2270-2276.
5. Wettergren A, Schjoldager B, Mortensen PE, Myhre J, Christiansen J, Holst JJ. Truncated GLP-1 (proglucagon 78-107-amide) inhibits gastric and pancreatic functions in man. Dig Dis Sci 1993; 38: 665-673.
6. Flint A, Raben A, Astrup A, Holst JJ. Glucagon-like peptide-1 promotes satiety and suppresses energy intake in humans. J Clin Invest 1998; 101: 515-520.
7. Deacon CF, Nauck MA, Toft-Nielsen M, Pridal L, Willms B, Holst JJ. Both subcutaneously and intravenously administered glucagon-like peptide I are rapidly degraded from the NH2-terminus in type II diabetic patients and in healthy subjects. Diabetes 1995; 44: 1126-1131.
8. Holst JJ, Deacon CF. Inhibition of the activity of dipeptidyl-peptidase IV as a treatment for type 2 diabetes. Diabetes 1998; 47: 1663-1670.
9. Deacon CF. Dipeptidyl peptidase-4 inhibitors in the treatment of type 2 diabetes: a comparative review. Diabetes Obes Metab 2001; 13: 7-18.
10. Rizza RA. Pathogenesis of fasting and postprandial hyperglycemia in type 2 diabetes: implications for therapy. Diabetes 2010; 59: 2697-2707.